2014
Diagnosis of bladder cancer and prediction of survival by urinary metabolomics
Jin X, Yun S, Jeong P, Kim I, Kim W, Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget 2014, 5: 1635-1645. PMID: 24721970, PMCID: PMC4039236, DOI: 10.18632/oncotarget.1744.Peer-Reviewed Original ResearchConceptsBladder cancerControl groupCancer groupCancer-specific survival timeMuscle-invasive bladder cancerInvasive bladder cancerMetabolomic profilesPrediction of survivalHigh-performance liquid chromatography-quadrupole timeLiquid chromatography-quadrupole timeUrinary metabolomicsCommon cancerControl subjectsUrinary cytologyBC diagnosisDiagnostic modalitiesSurvival timeCurrent modalitiesUrine metabolitesMetabolomics-based approachPatientsCancerDifferential metabolitesClinical applicabilityCarnitine transferase
2012
Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer
Yun S, Yoon H, Bae S, Lee O, Choi Y, Moon S, Kim I, Kim W. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer. Prostate Cancer And Prostatic Diseases 2012, 15: 369-373. PMID: 22890388, DOI: 10.1038/pcan.2012.31.Peer-Reviewed Original ResearchConceptsMetastatic diseaseGleason scoreProstate cancerMRNA expressionElevated PSA levelsNon-metastatic diseaseCase-control studyLow Gleason scoreRunx2 expressionHuman prostate tissuePSA levelsBPH patientsClinicopathological characteristicsClinicopathological outcomesCommon cancerLower PSAPrognostic markerReal-time PCRImmunohistochemical stainingImmunohistochemical analysisTranscription factor 2BPH controlProstate tissueRunx2 mRNA expressionCaP aggressiveness